Review of Current Strategies for Delivering Alzheimer's Disease Drugs Across the Blood-Brain Barrier

作者：Ka Hong Wong, Muhammad Kashif Riaz, Yuning Xie, Xue Zhang, Qiang Liu, Huoji Chen, Zhaoxiang Bian, Xiaoyu Chen, Aiping Lü, Zhijun Yang · 发表于：FOCUS The Journal of Lifelong Learning in Psychiatry · 年份：2022 · DOI：10.1176/appi.focus.20106 · 被引用次数：12 · 研究领域：Nanoparticle-Based Drug Delivery、Advanced Drug Delivery Systems、Alzheimer's disease research and treatments

Effective therapy for Alzheimer's disease is a major challenge in the pharmaceutical sciences. There are six FDA approved drugs (e.g., donepezil, memantine) that show some effectiveness; however, they only relieve symptoms. Two factors hamper research. First, the cause of Alzheimer's disease is not fully understood. Second, the blood-brain barrier restricts drug efficacy. This review summarized current knowledge relevant to both of these factors. First, we reviewed the pathophysiology of Alzheimer's disease. Next, we reviewed the structural and biological properties of the blood-brain barrier. We then described the most promising drug delivery systems that have been developed in recent years; these include polymeric nanoparticles, liposomes, metallic nanoparticles and cyclodextrins. Overall, we aim to provide ideas and clues to design effective drug delivery systems for penetrating the blood-brain barrier to treat Alzheimer's disease. (Appeared originally in the International Journal of Molecular Sciences 2019; 20:381) Reprinted under Creative Commons CC-BY license